Host |
Mouse |
Clone |
DBM15.60 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Adrenal gland |
Dilution |
1:50 - 1:100 |
Isotype |
IgG2b kappa |
Immunogen |
Recombinant human Adipophilin protein fragment. |
Localization |
Cytoplasm |
Adipophilin
|
DBM15.60 |
0.1 ml |
Concentrate |
CE/IVD |
MOB534-01 |
-
|
Host |
Mouse |
Clone |
DBM15.60 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Adrenal gland |
Dilution |
1:50 - 1:100 |
Isotype |
IgG2b kappa |
Immunogen |
Recombinant human Adipophilin protein fragment |
Localization |
Cytoplasm |
Adipophilin
|
DBM15.60 |
0.5 ml |
Concentrate |
CE/IVD |
MOB534-05 |
-
|
Host |
Mouse |
Clone |
DBM15.60 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Adrenal gland |
Dilution |
- |
Isotype |
IgG2b kappa |
Immunogen |
Recombinant human Adipophilin protein fragment |
Localization |
Cytoplasm |
Adipophilin
|
DBM15.60 |
6 ml |
Ready-to-use |
CE/IVD |
PDM534 |
-
|
Host |
Mouse |
Clone |
C3 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
HIER or PIER |
Positive control |
Fetal liver or hepatocellular carcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2a / kappa |
Immunogen |
Alpha fetoprotein (AFP) purified from serum of a hepatoma patient |
Localization |
Cytoplasm |
AFP
|
C3 |
1 ml |
Concentrate |
CE/IVD |
Z2623ML |
-
|
Host |
Mouse |
Clone |
C3 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
HIER or PIER |
Positive control |
Fetal liver or hepatocellular carcinoma. |
Dilution |
- |
Isotype |
IgG2a / kappa |
Immunogen |
Alpha fetoprotein (AFP) purified from serum of a hepatoma patient |
Localization |
Cytoplasm |
AFP
|
C3 |
7 ml |
Ready-to-use |
CE/IVD |
Z2623MP |
-
|
Host |
Mouse |
Clone |
C3 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
HIER or PIER |
Positive control |
Fetal liver or hepatocellular carcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2a / kappa |
Immunogen |
Alpha fetoprotein (AFP) purified from serum of a hepatoma patient |
Localization |
Cytoplasm |
AFP
|
C3 |
0.5 ml |
Concentrate |
CE/IVD |
Z2623MS |
-
|
Host |
Mouse |
Clone |
C3 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
HIER or PIER |
Positive control |
Fetal liver or hepatocellular carcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2a / kappa |
Immunogen |
Alpha fetoprotein (AFP) purified from serum of a hepatoma patient |
Localization |
Cytoplasm |
AFP
|
C3 |
0.1 ml |
Concentrate |
CE/IVD |
Z2623MT |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P, WB |
Pretreatment |
- |
Positive control |
Fetal Liver |
Dilution |
1:200 |
Isotype |
Rabbit IgG |
Immunogen |
Human alpha-fetoprotein purified from human cord serum |
Localization |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
polyclonal |
1 ml |
Concentrate |
RUO |
501-2954 |
-
|
Host |
Rabbit |
Clone |
SP154 |
Format |
Concentrate |
Method |
P, WB |
Pretreatment |
Citrate |
Positive control |
Hepatocellular Carcinoma |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Purified human AFP |
Localization |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
SP154 |
0.1 ml |
Concentrate |
RUO |
501-4540 |
-
|
Host |
Rabbit |
Clone |
SP154 |
Format |
Concentrate |
Method |
P, WB |
Pretreatment |
Citrate |
Positive control |
Hepatocellular Carcinoma |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Purified human AFP |
Localization |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
SP154 |
0.5 ml |
Concentrate |
RUO |
501-4542 |
-
|
Host |
Rabbit |
Clone |
SP154 |
Format |
Concentrate |
Method |
P, WB |
Pretreatment |
Citrate |
Positive control |
Hepatocellular Carcinoma |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Purified human AFP |
Localization |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
SP154 |
1 ml |
Concentrate |
RUO |
501-4544 |
-
|
Host |
Mouse |
Clone |
C3 |
Format |
Concentrate |
Method |
F, P |
Positive control |
Fetal Liver |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG2a |
Localization |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
C3 |
1 ml |
Concentrate |
CE/IVD |
MOB129 |
-
|
Host |
Mouse |
Clone |
C3 |
Format |
Concentrate |
Method |
F, P |
Positive control |
Fetal Liver |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG2a |
Localization |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
C3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB129-01 |
-
|
Host |
Mouse |
Clone |
C3 |
Format |
Concentrate |
Method |
F, P |
Positive control |
Fetal Liver |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG2a |
Localization |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
C3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB129-05 |
-
|
Host |
Mouse |
Clone |
C3 |
Format |
Ready-to-use |
Method |
F, P |
Positive control |
Fetal Liver |
Dilution |
- |
Isotype |
Mouse IgG2a |
Localization |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
C3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM057 |
-
|
Host |
Mouse |
Clone |
7E1 |
Format |
Concentrate |
Method |
F, WB, EL, IP |
Isotype |
IgG1 |
Immunogen |
Purified human articulate cartilage Aggregan |
Aggrecan
|
7E1 |
0.2 mg (1 mg/ml) |
Concentrate |
RUO |
601-0091C |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P, WB |
Pretreatment |
Citrate |
Positive control |
Lung Carcinoma |
Dilution |
1:50 |
Isotype |
Rabbit IgG |
Immunogen |
A synthetic peptide from N-terminaus of human Akt1. |
Localization |
Cytoplasm |
Akt1/2
|
polyclonal |
1 ml |
Concentrate |
RUO |
501-10844 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast carcinoma |
Dilution |
1:25 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide derived from the region of human AKT-1 that contains phosphorylated site of serine 473 |
Localization |
Cytoplasma, nucleus |
Akt1, phosphorylated Ser473
|
polyclonal |
0.1 ml |
Concentrate |
RUO |
501-13450 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast Carcinoma |
Dilution |
1:25 |
Isotype |
Rabbit IgG |
Immunogen |
A synthetic peptide corresponding to the carboxyl terminus of AKT1/PKB alpha of human origin at the phosphorylated site of Serine 473. |
Localization |
Cytoplasm (Nuclear) |
Akt1, phosphorylated Ser473
|
polyclonal |
1 ml |
Concentrate |
RUO |
501-13454 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Serum |
Method |
F, EL, WB |
Isotype |
Rabbit IgG |
Immunogen |
Bovine albumin |
Albumin (Bovine) (BSA)
|
polyclonal |
1 ml |
Serum |
RUO |
601-0351 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Positive control |
Liver |
Dilution |
1:50 - 1:1000 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Albumin (HSA)
|
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP046 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Positive control |
Liver |
Dilution |
1:50 - 1:1000 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Albumin (HSA)
|
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP046-01 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Positive control |
Liver |
Dilution |
1:50 - 1:1000 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Albumin (HSA)
|
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP046-05 |
-
|
Host |
Mouse |
Clone |
DBM15.81 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Proteinase K |
Dilution |
1:25 - 1:50 |
Immunogen |
Recombinant full-length ALB-protein |
Albumin - CF 488
|
DBM15.81 |
1 ml |
Concentrate |
CE/IVD |
FLC215 |
-
|
Host |
Mouse |
Clone |
DBM15.81 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Proteinase K |
Dilution |
1:25 - 1:50 |
Immunogen |
Recombinant full-length ALB-protein |
Albumin - CF 488
|
DBM15.81 |
0.1 ml |
Concentrate |
CE/IVD |
FLC215-01 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Purified |
Method |
F, EL |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding to the amino acids 1-3 of the native molecule conjugated to bovine serum albumin |
Aldosterone
|
polyclonal |
1 ml |
Purified |
RUO |
601-0145 |
-
|
Host |
Mouse |
Clone |
5A4 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Anaplastic large cell lymphoma |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm and nucleus (dot-like) |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
5A4 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3041A |
-
|
Host |
Mouse |
Clone |
5A4 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Anaplastic large cell lymphoma |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm and nucleus (dot-like) |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
5A4 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3041B |
-
|
Host |
Mouse |
Clone |
5A4 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Anaplastic large cell lymphoma |
Dilution |
- |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm and nucleus (dot-like) |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
5A4 |
6 ml |
Ready-to-use |
CE/IVD |
API3041AA |
-
|
Host |
Mouse |
Clone |
5A4 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Anaplastic Lymphoma |
Dilution |
1:25 - 1:75 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm, nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
5A4 |
1 ml |
Concentrate |
CE/IVD |
MOB416 |
-
|
Host |
Mouse |
Clone |
5A4 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Anaplastic Lymphoma |
Dilution |
1:25 - 1:75 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm, nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
5A4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB416-01 |
-
|
Host |
Mouse |
Clone |
5A4 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Anaplastic Lymphoma |
Dilution |
1:25 - 1:75 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm, nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
5A4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB416-05 |
-
|
Host |
Mouse |
Clone |
5A4 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Anaplastic large cell lymphoma |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm, nucleus (dot-like) |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
5A4 |
0.5 ml |
Concentrate |
CE/IVD |
MSK096-05 |
-
|
Host |
Mouse |
Clone |
1A4 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Anaplastic large cell lymphoma |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG2b |
Localization |
Cytoplasm, Nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
1A4 |
0.1 ml |
Concentrate |
RUO |
R0001MA01-MA |
-
|
Host |
Mouse |
Clone |
1A4 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Anaplastic large cell lymphoma |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG2b |
Localization |
Cytoplasm, Nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
1A4 |
0.5 ml |
Concentrate |
RUO |
R0001MA05-MA |
-
|
Host |
Rabbit |
Clone |
ZR305 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Anaplastic large cell lymphoma or lung |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Human ALK-protein fragment around aa 1058 - 1620 |
Localization |
Cytoplasm and nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
ZR305 |
1 ml |
Concentrate |
CE/IVD |
Z2534RL |
-
|
Host |
Rabbit |
Clone |
ZR305 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Anaplastic large cell lymphoma or lung |
Dilution |
- |
Isotype |
IgG |
Immunogen |
Human ALK-protein fragment around aa 1058 - 1620 |
Localization |
Cytoplasm and nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
ZR305 |
7 ml |
Ready-to-use |
CE/IVD |
Z2534RP |
-
|
Host |
Rabbit |
Clone |
ZR305 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Anaplastic large cell lymphoma or lung |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Human ALK-protein fragment around aa 1058 - 1620 |
Localization |
Cytoplasm and nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
ZR305 |
0.5 ml |
Concentrate |
CE/IVD |
Z2534RS |
-
|
Host |
Rabbit |
Clone |
ZR305 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Anaplastic large cell lymphoma or lung |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Human ALK-protein fragment around aa 1058 - 1620 |
Localization |
Cytoplasm and nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
ZR305 |
0.1 ml |
Concentrate |
CE/IVD |
Z2534RT |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P, WB |
Pretreatment |
- |
Positive control |
Tonsil |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Purified human alpha-1-antichymotrypsin |
Localization |
Cytoplasm |
Alpha-1-Antichymotrypsin
|
polyclonal |
1 ml |
Concentrate |
RUO |
501-3454 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Ready-to-use |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Alpha-1-Antichymotrypsin
|
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR023 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Alpha-1-Antichymotrypsin
|
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP047 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Alpha-1-Antichymotrypsin
|
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP047-01 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Alpha-1-Antichymotrypsin
|
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP047-05 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Ready-to-use |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Alpha-1-Antitrypsin (AAT)
|
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR021 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Alpha-1-Antitrypsin (AAT)
|
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP048 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Alpha-1-Antitrypsin (AAT)
|
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP048-01 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasm |
Alpha-1-Antitrypsin (AAT)
|
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP048-05 |
-
|
Host |
Mouse |
Clone |
INN-hFSH 100 |
Format |
Purified |
Method |
EL |
Isotype |
Mouse IgG1 |
Immunogen |
Human FSH |
alpha2-HCG (Human Chorionic Gonadotropin)
|
INN-hFSH 100 |
500 µg |
Purified |
RUO |
601-0178 |
-
|
Host |
Rabbit and Mouse |
Clone |
13H4 + ZM70 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Prostate carcinoma. |
Dilution |
1:50 |
Isotype |
IgG, IgG1a/k |
Immunogen |
Human AMACR (P504S) and p63 polypeptides |
Localization |
Cytoplasm and Nucleus |
AMACR + p63
|
13H4 + ZM70 |
1.0 ml |
Concentrate |
CE/IVD |
Z2008MRL |
-
|